{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:30:27Z","timestamp":1759941027792},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-016-0449-2","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T01:09:21Z","timestamp":1483664961000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Pravesh Kumar","family":"Bundhun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Zafooruddin Sani","family":"Soogund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek Rishikesh","family":"Teeluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Pursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Bhurtu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"issue":"8","key":"449_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation\u00a0as an\u00a0independent\u00a0risk factor\u00a0for\u00a0stroke: the\u00a0Framingham\u00a0study. Stroke. 1991;22(8):983\u20138.","journal-title":"Stroke"},{"issue":"1","key":"449_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40256-013-0050-3","volume":"14","author":"D Kim","year":"2014","unstructured":"Kim D, Barna R, Bridgeman MB, Brunetti L. Novel\u00a0oral\u00a0anticoagulants\u00a0for stroke prevention in the geriatric population. Am J Cardiovasc Drugs. 2014;14(1):15\u201329.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"20","key":"449_CR3","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","volume":"126","author":"F Dentali","year":"2012","unstructured":"Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy\u00a0and\u00a0safety\u00a0of the\u00a0novel\u00a0oral\u00a0anticoagulants\u00a0in\u00a0atrial fibrillation: a\u00a0systematic review\u00a0and\u00a0meta-analysis\u00a0of the\u00a0literature. Circulation. 2012;126(20):2381\u201391.","journal-title":"Circulation"},{"issue":"4","key":"449_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bcp.12376","volume":"78","author":"YK Loke","year":"2014","unstructured":"Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative\u00a0coronary\u00a0risks\u00a0of\u00a0apixaban,\u2009rivaroxaban\u00a0and\u00a0dabigatran: a\u00a0meta-analysis\u00a0and\u00a0adjusted\u00a0indirect comparison. Br J Clin Pharmacol. 2014;78(4):707\u201317.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"449_CR5","first-page":"330","volume":"31","author":"J Harenberg","year":"2012","unstructured":"Harenberg J, Marx S, Diener HC, et al. Comparison\u00a0of\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0dabigatran,\u2009rivaroxaban\u00a0and\u00a0apixaban\u00a0in\u00a0patients\u00a0with\u00a0atrial fibrillation using\u00a0network\u00a0meta-analysis. Int Angiol. 2012;31(4):330\u20139.","journal-title":"Int Angiol"},{"key":"449_CR6","doi-asserted-by":"crossref","unstructured":"Higgins JPT AD. Cochrane handbook for systematic reviews of interventions: Wiley; 2008","DOI":"10.1002\/9780470712184"},{"key":"449_CR7","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The\u00a0PRISMA\u00a0statement\u00a0for\u00a0reporting\u00a0systematic\u00a0reviews\u00a0and\u00a0meta-analyses\u00a0of\u00a0studies\u00a0that\u00a0evaluate\u00a0healthcareinterventions:\u2009explanation\u00a0and\u00a0elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"449_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4034","author":"A Gorst-Rasmussen","year":"2016","unstructured":"Gorst-Rasmussen A, Lip GY, Bjerregaard LT. Rivaroxaban\u00a0versus\u00a0warfarin\u00a0and\u00a0dabigatran\u00a0in\u00a0atrial\u00a0fibrillation:\u2009comparative\u00a0effectiveness\u00a0and\u00a0safety\u00a0in Danish\u00a0routine\u00a0care. Pharmaco epidemiol Drug Saf. 2016. doi: 10.1002\/pds.4034 .","journal-title":"Pharmaco epidemiol Drug Saf"},{"issue":"10","key":"449_CR9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1060028014540868","volume":"48","author":"AS Larock","year":"2014","unstructured":"Larock AS, Mullier F, Sennesael AL, et al. Appropriateness\u00a0of\u00a0prescribing\u00a0dabigatran etexilate\u00a0and\u00a0rivaroxaban\u00a0in\u00a0patients\u00a0with\u00a0nonvalvular\u00a0atrial fibrillation: a\u00a0prospective study. Ann Pharmacother. 2014;48(10):1258\u201368.","journal-title":"Ann Pharmacother"},{"issue":"13","key":"449_CR10","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","volume":"132","author":"G Maura","year":"2015","unstructured":"Maura G, Bloti\u00e8re PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M. Comparison\u00a0of the\u00a0short-term\u00a0risk of\u00a0bleeding\u00a0and\u00a0arterial\u00a0thromboembolic events\u00a0in\u00a0nonvalvular\u00a0atrial fibrillation\u00a0patients\u00a0newly\u00a0treated\u00a0with\u00a0dabigatran\u00a0or\u00a0rivaroxaban\u00a0versus\u00a0vitamin K\u00a0antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132(13):1252\u201360.","journal-title":"Circulation"},{"issue":"8","key":"449_CR11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/europace\/euu007","volume":"16","author":"R Provid\u00eancia","year":"2014","unstructured":"Provid\u00eancia R, Marijon E, Albenque JP, et al. Rivaroxaban\u00a0and\u00a0dabigatran\u00a0in\u00a0patients\u00a0undergoing\u00a0catheter\u00a0ablation\u00a0of\u00a0atrial\u00a0fibrillation. Europace. 2014;16(8):1137\u201344.","journal-title":"Europace"},{"issue":"2","key":"449_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000365967","volume":"90","author":"M Sherid","year":"2014","unstructured":"Sherid M, Sifuentes H, Sulaiman S, et al. Risk\u00a0of\u00a0gastrointestinal\u00a0bleeding\u00a0with\u00a0dabigatran: a\u00a0head-to-head\u00a0comparative\u00a0study\u00a0with\u00a0rivaroxaban. Digestion. 2014;90(2):137\u201346.","journal-title":"Digestion"},{"issue":"1","key":"449_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2042098615618171","volume":"7","author":"EY Chen","year":"2016","unstructured":"Chen EY, Diug B, Bell JS, et al. Spontaneously\u00a0reported\u00a0haemorrhagic\u00a0adverse\u00a0events\u00a0associated\u00a0with\u00a0rivaroxaban\u00a0and\u00a0dabigatran\u00a0in Australia. Ther Adv Drug Saf. 2016;7(1):4\u201310.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"449_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jce.12856","volume":"27","author":"A Rillig","year":"2016","unstructured":"Rillig A, Lin T, Plesman J, et al. Apixaban,\u2009rivaroxaban, and\u00a0dabigatran\u00a0in\u00a0patients\u00a0undergoing\u00a0atrial fibrillation\u00a0ablation. J Cardiovasc Electrophysiol. 2016;27(2):147\u201353.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"7","key":"449_CR15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/1076029614536606","volume":"20","author":"GV Fontaine","year":"2014","unstructured":"Fontaine GV, Mathews KD, Woller SC, Stevens SM, Lloyd JF, Evans RS. Major\u00a0bleeding\u00a0with\u00a0dabigatran\u00a0and\u00a0rivaroxaban\u00a0in\u00a0patients\u00a0with\u00a0atrial fibrillation: a\u00a0real-world\u00a0setting. Clin Appl Thromb Hemost. 2014;20(7):665\u201372.","journal-title":"Clin Appl Thromb Hemost"},{"key":"449_CR16","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","volume":"350","author":"NS Abraham","year":"2015","unstructured":"Abraham NS, Singh S, Alexander GC, et al. Comparative\u00a0risk of\u00a0gastrointestinal bleeding\u00a0with\u00a0dabigatran,\u2009rivaroxaban, and\u00a0warfarin:\u2009population\u00a0based cohort study. BMJ. 2015;350:h1857.","journal-title":"BMJ"},{"issue":"5","key":"449_CR17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2015.01.159","volume":"47","author":"L Loffredo","year":"2015","unstructured":"Loffredo L, Perri L, Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials. Dig Liver Dis. 2015;47(5):429\u201331.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"449_CR18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bcp.12376","volume":"78","author":"YK Loke","year":"2014","unstructured":"Loke YK, Pradhan S, JK-y Y, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707\u201317.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"449_CR19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00392-015-0821-8","volume":"104","author":"D Caldeira","year":"2015","unstructured":"Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ. Non-vitamin\u00a0K\u00a0antagonist\u00a0oral\u00a0anticoagulants\u00a0in the\u00a0cardioversion\u00a0of\u00a0patients\u00a0with\u00a0atrial\u00a0fibrillation:\u2009systematicreview\u00a0and\u00a0meta-analysis. Clin Res Cardiol. 2015;104(7):582\u201390.","journal-title":"Clin Res Cardiol"},{"key":"449_CR20","doi-asserted-by":"crossref","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6).","DOI":"10.1161\/JAHA.116.003725"},{"key":"449_CR21","doi-asserted-by":"crossref","unstructured":"Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis. J Am Heart Assoc. 2016;5(5).","DOI":"10.1161\/JAHA.116.003206"},{"issue":"1","key":"449_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40261-013-0144-3","volume":"34","author":"C Rognoni","year":"2014","unstructured":"Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban,\u2009dabigatran, and\u00a0rivaroxaban\u00a0versus\u00a0warfarin\u00a0for\u00a0stroke\u00a0prevention\u00a0in\u00a0non-valvular\u00a0atrial\u00a0fibrillation: a cost-effectiveness\u00a0analysis. Clin Drug Investig. 2014;34(1):9\u201317.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"449_CR23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1160\/TH12-06-0388","volume":"108","author":"AR Kansal","year":"2012","unstructured":"Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran\u00a0versus\u00a0rivaroxaban\u00a0for the\u00a0prevention\u00a0of\u00a0stroke\u00a0and\u00a0systemic\u00a0embolism\u00a0in\u00a0atrial fibrillation\u00a0in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost. 2012;108(4):672\u201382.","journal-title":"Thromb Haemost"},{"issue":"3","key":"449_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.repc.2015.09.009","volume":"35","author":"L Silva Miguel","year":"2016","unstructured":"Silva Miguel L, Ferreira J. Clinical\u00a0and\u00a0economic\u00a0consequences\u00a0of using\u00a0dabigatran\u00a0or\u00a0rivaroxaban\u00a0in\u00a0patients\u00a0with\u00a0non-valvular\u00a0atrial fibrillation. Rev Port Cardiol. 2016;35(3):141\u20138.","journal-title":"Rev Port Cardiol"},{"issue":"1","key":"449_CR25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13063-016-1541-8","volume":"17","author":"JB Kim","year":"2016","unstructured":"Kim JB, Joung HJ, Lee JM, et al. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a\u00a0randomized\u00a0controlled\u00a0trial. Trials. 2016;17(1):422.","journal-title":"Trials"},{"issue":"3","key":"449_CR26","volume":"9","author":"J-C Lega","year":"2014","unstructured":"Lega J-C, Bertoletti L, Gremillet C, Chapelle C, Mismetti P, Cucherat M, Vital-Durand D, Laporte S. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One. 2014;9(3), e91398.","journal-title":"PLoS One"},{"issue":"2","key":"449_CR27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11239-013-0956-2","volume":"36","author":"SD Pokorney","year":"2013","unstructured":"Pokorney SD, Sherwood MW, Becker RC. Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis. 2013;36(2):163\u201374.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"449_CR28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","volume":"129","author":"Z Hijazi","year":"2014","unstructured":"Hijazi Z, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in\u00a0patients\u00a0with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961\u201370.","journal-title":"Circulation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T06:17:14Z","timestamp":1568701034000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-016-0449-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0449-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]},"article-number":"15"}}